Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia

被引：0

作者：

Vinod Pullarkat ^{[1
]}

Keith W. Pratz ^{[2
]}

Hartmut Döhner ^{[3
]}

Christian Recher ^{[4
]}

Michael J. Thirman ^{[5
]}

Courtney D. DiNardo ^{[6
]}

Pierre Fenaux ^{[7
]}

Andre C. Schuh ^{[8
]}

Andrew H. Wei ^{[9
]}

Arnaud Pigneux ^{[10
]}

Jun-Ho Jang ^{[11
]}

Gunnar Juliusson ^{[12
]}

Yasushi Miyazaki ^{[13
]}

Dominik Selleslag ^{[14
]}

Martha L. Arellano ^{[15
]}

Chenglong Liu ^{[16
]}

Jean A. Ridgeway ^{[16
]}

Jalaja Potluri ^{[16
]}

Jovita Schuler ^{[16
]}

Marina Konopleva ^{[6
]}

机构：

[1] City of Hope Comprehensive Cancer Center,Department of Hematology and Hematopoietic Cell Transplantation and Gehr Family Center for Leukemia Research

[2] University of Pennsylvania,Abramson Cancer Center

[3] Ulm University Hospital,Department of Internal Medicine III

[4] Centre Hospitalier Universitaire de Toulouse,Section of Hematology/Oncology, Department of Medicine

[5] The University of Chicago Medicine,Department of Medical Oncology and Hematology

[6] Montefiore-Einstein Comprehensive Cancer Center,Peter MacCallum Cancer Centre, Royal Melbourne Hospital

[7] Hôpital St. Louis/Assistance Publique-Hôpitaux de Paris and Université de Paris,Department of Hematology

[8] Princess Margaret Cancer Centre,Department of Hematology

[9] Walter and Eliza Hall Institute of Medical Research and University of Melbourne,Oncology, Samsung Medical Center

[10] CHU de Bordeaux,Department of Hematology

[11] Sungkyunkwan University School of Medicine,Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute

[12] Skåne University Hospital,Department of Hematology and Medical Oncology, Winship Cancer Institute

[13] Nagasaki University,undefined

[14] Algemeen Ziekenhuis Sint-Jan,undefined

[15] Emory University School of Medicine,undefined

[16] AbbVie Inc.,undefined

来源：

Blood Cancer Journal | / 15卷 / 1期

关键词：

D O I：

10.1038/s41408-025-01263-3

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Therapy-related Myeloid Neoplasms, Antecedent Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Pullarkat, Vinod
Pratz, Keith W.
Doehner, Hartmut
Recher, Christian
Thirman, Michael J.
DiNardo, Courtney D.
Fenaux, Pierre
Schuh, Andre C.
Wei, Andrew H.
Pigneux, Arnaud
Jang, Jun-Ho
Juliusson, Gunnar
Miyazaki, Yasushi
Selleslag, Dominik
Arellano, Martha L.
Naqvi, Kiran
Yu, Jun
Ridgeway, Jean A.
Potluri, Jalaja
Konopleva, Marina
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 58 - 59
[2] Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia
Meers, S.
Selleslag, D.
Potier, H.
Glasmacher, A.
Mineur, P.
Voelter, V.
CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (01) : 35 - 42
[3] Venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with therapy-related myeloid neoplasms, antecedent myelodysplastic syndromes, or myelodysplastic/myeloproliferative neoplasms.
Pullarkat, Vinod
Pratz, Keith
Dohner, Hartmut
Recher, Christian
Thirman, Michael J.
Dinardo, Courtney Denton
Fenaux, Pierre
Schuh, Andre C.
Wei, Andrew H.
Pigneux, Arnaud
Jang, Jun Ho
Juliusson, Gunnar
Miyazaki, Kazuhito
Selleslag, Dominik
Arellano, Martha Lucia
Naqvi, Kiran
Yu, Jun
Ridgeway, Jean
Potluri, Jalaja
Konopleva, Marina
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[4] 5-Azacitidine Therapy in Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia: a Single Institution Experience
Freyrie, Alessandra
Reda, Gianluigi
Vincenti, Daniele
Sciume, Mariarita
Binda, Francesca
Guidotti, Francesca
Cortelezzi, Agostino
BLOOD, 2012, 120 (21)
[5] Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment
Calleja, Anne
Yun, Seongseok
Moreilhon, Chimene
Karsenti, Jean Michel
Gastaud, Lauris
Mannone, Lionel
Komrokji, Rami
al Ali, Najla
Dadone-montaudie, Berangere
Robert, Guillaume
Auberger, Patrick
Raynaud, Sophie
Sallman, David A.
Cluzeau, Thomas
EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (05) : 488 - 498
[6] Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
Garcia-Manero, Guillermo
Gore, Steven D.
Cogle, Christopher
Ward, Renee
Shi, Tao
MacBeth, Kyle J.
Laille, Eric
Giordano, Heidi
Sakoian, Sarah
Jabbour, Elias
Kantarjian, Hagop
Skikne, Barry
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18) : 2521 - 2527
[7] Results of 5-azacitidine therapy in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML)
Freyrie, A.
Reda, G.
Vincenti, D.
Ferla, V.
Orofino, N.
Sciume, M.
Guidotti, F.
Cortelezzi, A.
LEUKEMIA RESEARCH, 2013, 37 : S157 - S158
[8] Health-Related Quality of Life in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Receiving Glasdegib plus Azacitidine
Wang, Eunice
Bell, Timothy
Zeidan, Amer
Bhattcharyya, Helen
Kudla, Arthur
Chan, Geoffrey
Sekeres, Mikkael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S191 - S191
[9] Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
DiNardo, C. D.
Jonas, B. A.
Pullarkat, V.
Thirman, M. J.
Garcia, J. S.
Wei, A. H.
Konopleva, M.
Doehner, H.
Letai, A.
Fenaux, P.
Koller, E.
Havelange, V.
Leber, B.
Esteve, J.
Wang, J.
Pejsa, V.
Hajek, R.
Porkka, K.
Illes, A.
Lavie, D.
Lemoli, R. M.
Yamamoto, K.
Yoon, S. -S.
Jang, J. -H.
Yeh, S. -P.
Turgut, M.
Hong, W. -J.
Zhou, Y.
Potluri, J.
Pratz, K. W.
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (07): : 617 - 629
[10] Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes
Shimony, Shai
Stone, Richard M.
Stahl, Maximilian
CURRENT OPINION IN HEMATOLOGY, 2022, 29 (02) : 63 - 73

← 1 2 3 4 5 →